Clayton A. Clark - Houston, TX

Clayton A. Clark is the managing partner of Clark, Love & Hutson, PLLC. Mr. Clark manages and supervises the firm's personal injury, products liability, pharmaceutical, intellectual property, and insurance litigation sections. He is a national trial lawyer with extensive multistate and multidistrict litigation experience. From signing up initial cases to obtaining jury verdicts in bellwether trials, Mr. Clark and his firm have earned a nationwide reputation for successfully developing and litigating mass tort actions, as well as coordinating and resolving complex litigation against Fortune 500 companies.

Mr. Clark has extensive multidistrict litigation leadership experience. Over the last several decades, he has been appointed to multiple leadership positions, including lead counsel, co-lead counsel, national liaison counsel, and executive committee member, in the following MDLs:

• In Re: Boston Scientific Corp., Pelvic Repair Systems Products Liability Litigation, MDL No. 2326;
• In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation, MDL No. 2385;
• In Re: Topamax, Philadelphia - Complex Litigation Center;
• In Re: Paxil, Philadelphia - Complex Litigation Center;
• In Re: Phenylpropanolamine (PPA) Products Liability, U.S. District Court of Washington at Seattle, MDL No. 1407;
• In Re: Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine), U.S. District Court Eastern District of Pennsylvania, MDL No. 1203;
• In Re: Rezulin Products Liability Litigation, U.S. District Court Southern District of New York, MDL No. 1348;
• In Re: Zyprexa Products Liability Litigation, U.S. District Court Eastern District of New York, MDL No. 1596;
• In Re: Texas City BP Explosion;
• In Re: Advair, Galveston County, Texas;
• In Re: Trasylol Products Liability Litigation, U.S. District Court Southern District of Florida, MDL No. 1928; and
• In Re: Avandia, Wharton County, Texas.

Mr. Clark currently serves as national Co-Lead Counsel in the Boston Scientific Corp., Pelvic Repair System Products Liability Litigation, MDL No. 2326. Additionally, he was selected to serve on the Plaintiffs' Executive Committee and the Plaintiffs' Steering Committee for five separate pelvic repair system products MDLs in the United States District Court for the Southern District of West Virginia:

• In Re: C.R. Bard, Inc., Pelvic Repair System Products Liability Litigation, MDL No. 2187;
• In Re: American Medical Systems, Inc., Pelvic Repair Systems Products Liability Litigation, MDL No. 2325;
• In Re: Boston Scientific Corp., Pelvic Repair Systems Products Liability Litigation, MDL No. 2326;
• In Re: Ethicon, Inc., Pelvic Repair System Products Liability Litigation, MDL No. 2327; and
• In Re: Coloplast Corp., Pelvic Support Systems Products Liability Litigation, MDL No. 2387.

Mr. Clark has also served as Plaintiffs' Liaison Counsel in the Phen-Fen Litigation and Paxil Birth Defects Cases, both in the Court of Common Pleas for Philadelphia County, Pennsylvania, and served on the PPA National Litigation Group Committee National Bankruptcy Committee for Toxic Tort/Dangerous Drug (Delaco Bankruptcy, New York, New York). In his role as national liaison counsel for the Paxil litigation, Mr. Clark coordinated the litigation, handled all hearings, and implemented the general and specific Plaintiff litigation strategies.

Mr. Clark also served on the Executive Committee of the Plaintiffs' Leadership Counsel in the Pradaxa (Dabigatran Etexilate) Products Liability Litigation assigned to the United States District Court for the Southern District of Illinois, MDL No. 2385. Not only did Clark, Love & Hutson contribute in the litigation itself, Mr. Clark's negotiations resulted in an expeditious settlement.

In addition to his leadership experience in multidistrict litigation, Mr. Clark has developed a national reputation for his ability to create and manage the settlement process, as highlighted by recent appointments in two separate federal MDLs. Most recently, in August 2017, Mr. Clark was one of four attorneys in the country to be appointed to the Plaintiffs' Settlement Negotiation Committee in the Syngenta AG MIR162 Corn Litigation, MDL No. 2591. The Syngenta litigation is the single largest agricultural litigation to date. Mr. Clark was also recently appointed by the Honorable Joseph R. Goodwin to the MDL Executive Fee Committee. Mr. Clark is responsible for overseeing the distribution of common benefit funds. In addition to these recent appointments, Mr. Clark has been instrumental in creating the framework for multiple MDL settlements in the transvaginal mesh litigation.